Brain Cancer | Specialty

Latest News & Insight: November 20, 2014

November 21st 2014

Experts Discuss Immunotherapy's Potential in Neuro-Oncology

November 17th 2014

Immunotherapy's promise as well as its challenges as a treatment for patients with brain cancer was the focus of a plenary session held November 15 at the Society of Neuro-Oncology's (SNO) 2014 Annual Meeting in Miami Beach.

Oncolytic Virus Shows Early Promise in Glioma

November 17th 2014

The oncolytic virus Delta-24-RGD can infect, replicate, and kill glioma cells in patients, according to phase I research presented at the 2014 Society for Neuro-Oncology (SNO) Annual Meeting in Miami.

Dr. de Groot Discusses Altiratinib as Potential Treatment for Glioblastoma

November 17th 2014

John F de Groot, MD, nuro-oncologist, MD Anderson Cancer Center, discusses the efficacy of the novel c-MET inhibitor altiratinib in glioblastoma.

Dr. Stupp Discusses NovoTTF With Temozolomide in Glioblastoma

November 16th 2014

Roger Stupp, MD, Professor of Oncology, University of Zürich; Chairman, Department of Oncology and Cancer Center, University of Zürich Hospital, Zürich, Switzerland, discusses the interim analysis of the EF-14 trial, which compared NovoTTF-100A together with temozolomide versus temozolomide alone in patients with newly diagnosed glioblastoma multiforme (GBM).

Survival Improvement With NovoTTF Leads to Early End of Phase III Trial

November 16th 2014

Use of the NovoTTF system along with adjuvant temozolomide led to longer progression-free survival and overall survival in patients with glioblastoma.

Dr. Butowski Discusses Dianhydrogalactitol in Patients with Recurrent GBM

November 16th 2014

Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I/II study of dianhydrogalacitol in patients with recurrent glioblastoma multiforme (GBM).

Rindopepimut Leads to Improved PFS in Compassionate Use Study

November 16th 2014

The vaccine rindopepimut appears to help PFS and OS in patients with epidermal growth factor receptor variant III mutation in glioblastoma-a patient group with traditionally poor outcomes.

Dr. van den Bent Discusses Bevacizumab Plus Lomustine in Recurrent Glioblastoma

November 15th 2014

Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands, discusses the BELOB trial, which examined bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma.

Dr. Reardon Discusses Rindopepimut Plus Bevacizumab in Glioblastoma

November 15th 2014

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, discusses the ReACT study, which examined the rindopepimut vaccine (CDX-110) plus bevacizumab in patients with relapsed glioblastoma.

Rindopepimut Plus Bevacizumab Shows Prolonged Survival in Recurrent Glioblastoma

November 15th 2014

The vaccine rindopepimut plus bevacizumab induced tumor regression in a subset of patients with recurrent glioblastoma.

Adding Lomustine to Bevacizumab Improves Outcomes in Recurrent Glioblastoma

November 14th 2014

The combination of bevacizumab and lomustine showed superior efficacy compared with either agent alone in patients with recurrent glioblastoma, warranting further study.

Dr. Verhaak Discusses Genomic Characterization of Diffuse Lower Grade Gliomas

November 14th 2014

Roeland GW Verhaak, PhD, Assistant Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the comprehensive and integrative genomic characterization of diffuse lower grade gliomas.

PCV Chemotherapy Plus Radiation Improves Survival in Low-Grade Glioma

November 14th 2014

The combination of radiation therapy with procarbazine, CCNU, and vincristine prolonged OS and PFS compared with radiation therapy alone in grade 2 glioma.

Dr. Toms on Targeting MEK as a Treatment Strategy for CNS Metastasis

November 14th 2014

Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses how targeting MEK can be an effective treatment strategy for CNS metastasis.

Dendritic Cell Vaccines Offer Promising Signals as Glioblastoma Therapy

August 29th 2014

Immunotherapy is rapidly emerging as a very attractive and novel therapeutic approach for cancer, including for glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults.

Evidence Builds for Electric Field Therapy in Recurrent GBM

August 19th 2014

A wearable device that uses electric fields to disrupt the activity of cancer cells has demonstrated survival benefits among patients with recurrent glioblastoma multiforme in real-world settings, particularly among individuals treated in earlier stages of progression

The Role of Radiation in the Management of Brain Metastases

March 6th 2014

In this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.

Dendritic Vaccine Improves Survival in Recurrent Glioblastoma

February 19th 2014

A personalized vaccine being tested as a therapy for recurrent glioblastoma multiforme (GBM) improved patient survival compared with standard treatments

The Awake Craniotomy Presents Advantages in Resection of Eloquent Cortex Brain Tumors

January 15th 2014

Awake craniotomies are traditionally reserved for, but not limited to, tumors involving the primary motor and speech areas